Gene Disease Score gda Association Type Original DB Sentence supporting the association PMID PMID Year
Entrez Id: 3845
Gene Symbol: KRAS
KRAS
CUI: C0029925
Disease: Ovarian Carcinoma
Ovarian Carcinoma
0.400 GeneticVariation BEFREE KRAS or BRAF mutation status is a useful predictor of sensitivity to MEK inhibition in ovarian cancer. 19018267

2009

Entrez Id: 3845
Gene Symbol: KRAS
KRAS
CUI: C0029925
Disease: Ovarian Carcinoma
Ovarian Carcinoma
0.400 GeneticVariation BEFREE KRAS mutation is a common event in ovarian cancer primarily in carcinomas of lower grade, lower FIGO stage, and mucinous histotype. 19358724

2009

Entrez Id: 3845
Gene Symbol: KRAS
KRAS
CUI: C0029925
Disease: Ovarian Carcinoma
Ovarian Carcinoma
0.400 Biomarker BEFREE KRAS and MAPK1 gene amplification in type II ovarian carcinomas. 23820584

2015

Entrez Id: 3845
Gene Symbol: KRAS
KRAS
CUI: C0029925
Disease: Ovarian Carcinoma
Ovarian Carcinoma
0.400 Biomarker BEFREE KRAS Genomic Status Predicts the Sensitivity of Ovarian Cancer Cells to Decitabine. 25968887

2015

Entrez Id: 3845
Gene Symbol: KRAS
KRAS
CUI: C0029925
Disease: Ovarian Carcinoma
Ovarian Carcinoma
0.400 GeneticVariation BEFREE KRAS mutation testing in borderline ovarian tumors and low-grade ovarian carcinomas with a rapid, fully integrated molecular diagnostic system. 28992761

2017

Entrez Id: 3845
Gene Symbol: KRAS
KRAS
CUI: C0029925
Disease: Ovarian Carcinoma
Ovarian Carcinoma
0.400 GeneticVariation BEFREE A KRAS-variant in ovarian cancer acts as a genetic marker of cancer risk. 20647319

2010

Entrez Id: 3845
Gene Symbol: KRAS
KRAS
CUI: C0029925
Disease: Ovarian Carcinoma
Ovarian Carcinoma
0.400 Biomarker BEFREE A KRAS variant is a biomarker of poor outcome, platinum chemotherapy resistance and a potential target for therapy in ovarian cancer. 22139083

2013

Entrez Id: 3845
Gene Symbol: KRAS
KRAS
CUI: C0029925
Disease: Ovarian Carcinoma
Ovarian Carcinoma
0.400 GeneticVariation BEFREE An assay for the single-nucleotide polymorphism (SNP), rs61764370, has recently been commercially marketed as a clinical test to aid ovarian cancer risk evaluation in women with family histories of the disease. rs67164370 is in a 3'-UTR miRNA binding site of the KRAS oncogene and is a candidate for epithelial ovarian cancer (EOC) susceptibility. 21385923

2011

Entrez Id: 3845
Gene Symbol: KRAS
KRAS
CUI: C0029925
Disease: Ovarian Carcinoma
Ovarian Carcinoma
0.400 GeneticVariation BEFREE Because of the similarity of the breast and ovarian cancer in the etiology of the diseases, amplification of c-erbB-2, c-myc and Ki-ras genes was examined in 32 ovarian carcinoma samples (stage I-IV). 7903645

1994

Entrez Id: 3845
Gene Symbol: KRAS
KRAS
CUI: C0029925
Disease: Ovarian Carcinoma
Ovarian Carcinoma
0.400 GeneticVariation BEFREE BRAF and KRAS mutations are common in serous borderline (SB) and LGS ovarian cancers, and MEK inhibition has been shown to induce tumor regression in a minority of patients; however, no correlation has been observed between mutation status and clinical response. 26324360

2016

Entrez Id: 3845
Gene Symbol: KRAS
KRAS
CUI: C0029925
Disease: Ovarian Carcinoma
Ovarian Carcinoma
0.400 AlteredExpression BEFREE By Northern blot analysis, elevated levels of c-Ki-ras and LDH-A mRNA transcripts were noted in 49% (17/35) and 40% (14/35) of ovarian cancers, respectively. 8995558

1997

Entrez Id: 3845
Gene Symbol: KRAS
KRAS
CUI: C0029925
Disease: Ovarian Carcinoma
Ovarian Carcinoma
0.400 GeneticVariation BEFREE Extensive sequence variation in the 3' untranslated region of the KRAS gene in lung and ovarian cancer cases. 24552817

2014

Entrez Id: 3845
Gene Symbol: KRAS
KRAS
CUI: C0029925
Disease: Ovarian Carcinoma
Ovarian Carcinoma
0.400 Biomarker BEFREE Here, we used a reverse-engineering approach in an ovarian cancer model to reconstruct KRAS oncogene-dependent cytoplasmic and transcriptional networks from perturbation experiments based on gene silencing and pathway inhibitor treatments. 22864383

2013

Entrez Id: 3845
Gene Symbol: KRAS
KRAS
CUI: C0029925
Disease: Ovarian Carcinoma
Ovarian Carcinoma
0.400 GeneticVariation BEFREE In the current study, the authors sought to determine whether BRAF or KRAS mutation status was associated with disease stage and/or histology in patients with SB and LGS ovarian cancer. 22930283

2013

Entrez Id: 3845
Gene Symbol: KRAS
KRAS
CUI: C0029925
Disease: Ovarian Carcinoma
Ovarian Carcinoma
0.400 GeneticVariation BEFREE Recently, a variant allele in the 3'UTR of the KRAS gene (rs61764370 T>G) was shown to be associated with an increased risk for developing non-small cell lung cancer, as well as ovarian cancer, and was most enriched in ovarian cancer patients from hereditary breast and ovarian cancer families. 20676756

2011

Entrez Id: 3845
Gene Symbol: KRAS
KRAS
CUI: C0029925
Disease: Ovarian Carcinoma
Ovarian Carcinoma
0.400 GeneticVariation BEFREE Role of KRAS and BRAF gene mutations in mucinous ovarian carcinoma. 12893203

2003

Entrez Id: 3845
Gene Symbol: KRAS
KRAS
CUI: C0029925
Disease: Ovarian Carcinoma
Ovarian Carcinoma
0.400 AlteredExpression BEFREE Several proto-oncogenes, such as AKT2 and Ki-RAS, are activated during ovarian cancer development, with putative oncogene-containing chromosomal regions showing imbalances and DNA amplifications. 9633840

1998

Entrez Id: 3845
Gene Symbol: KRAS
KRAS
CUI: C0029925
Disease: Ovarian Carcinoma
Ovarian Carcinoma
0.400 Biomarker BEFREE Taken together, our findings suggest that miR-613 functions as a candidate tumor suppressor miRNA in ovarian cancer by directly targeting KRAS. 26631045

2017

Entrez Id: 3845
Gene Symbol: KRAS
KRAS
CUI: C0029925
Disease: Ovarian Carcinoma
Ovarian Carcinoma
0.400 GeneticVariation BEFREE The KRAS-variant is associated with risk of developing double primary breast and ovarian cancer. 22662244

2012

Entrez Id: 3845
Gene Symbol: KRAS
KRAS
CUI: C0029925
Disease: Ovarian Carcinoma
Ovarian Carcinoma
0.400 GeneticVariation BEFREE The apparent restriction of these BRAF and KRAS mutations to low-grade serous ovarian carcinoma and its precursors suggests that low-grade and high-grade ovarian serous carcinomas develop through independent pathways. 12644542

2003

Entrez Id: 3845
Gene Symbol: KRAS
KRAS
CUI: C0029925
Disease: Ovarian Carcinoma
Ovarian Carcinoma
0.400 GeneticVariation BEFREE The high frequency of PI3KCA mutations, the low rate of mutations in KRAS and the absence of mutations in BRAF, indicate a molecular signature of OCCCs different from other ovarian carcinomas. 27153872

2017

Entrez Id: 3845
Gene Symbol: KRAS
KRAS
CUI: C0029925
Disease: Ovarian Carcinoma
Ovarian Carcinoma
0.400 GeneticVariation BEFREE The results of the present study suggested that a presence of KRAS mutations in mucinous ovarian cancer and CFDNA and p53-Ab in serous tumors was correlated with the highest risk of cancer progression. 21098618

2011

Entrez Id: 3845
Gene Symbol: KRAS
KRAS
CUI: C0029925
Disease: Ovarian Carcinoma
Ovarian Carcinoma
0.400 AlteredExpression BEFREE Using DNA extracted from paraffin embedded tissue, polymerase chain reaction amplification, designed restriction fragment length polymorphism analysis, and DNA sequencing, 1 cystadenoma (5%), 6 LMP tumors (30%), and 1 ovarian carcinoma (4%) demonstrated an activated Ki-ras gene. 8319218

1993

Entrez Id: 3845
Gene Symbol: KRAS
KRAS
CUI: C0029925
Disease: Ovarian Carcinoma
Ovarian Carcinoma
0.400 Biomarker BEFREE We found no evidence of disease association for SNPs in BRAF, KRAS, ERBB2 and PIK3CA when OC was considered as a single disease phenotype; but after stratification by histological subtype, we found borderline evidence of association for SNPs in KRAS and BRAF with mucinous OC and in ERBB2 and PIK3CA with endometrioid OC. 19240718

2009